Effects of Fixed-dose Enalapril/Lercanidipine on Biomarkers of Cardiovascular Risk in Hypertensive Patients

Trial Profile

Effects of Fixed-dose Enalapril/Lercanidipine on Biomarkers of Cardiovascular Risk in Hypertensive Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Lercanidipine/enalapril (Primary) ; Enalapril; Lercanidipine
  • Indications Essential hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 02 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top